263 related articles for article (PubMed ID: 29883886)
1. iPSC-derived neurons of CREBBP- and EP300-mutated Rubinstein-Taybi syndrome patients show morphological alterations and hypoexcitability.
Alari V; Russo S; Terragni B; Ajmone PF; Sironi A; Catusi I; Calzari L; Concolino D; Marotta R; Milani D; Giardino D; Mantegazza M; Gervasini C; Finelli P; Larizza L
Stem Cell Res; 2018 Jul; 30():130-140. PubMed ID: 29883886
[TBL] [Abstract][Full Text] [Related]
2. Rubinstein-Taybi 2 associated to novel EP300 mutations: deepening the clinical and genetic spectrum.
López M; García-Oguiza A; Armstrong J; García-Cobaleda I; García-Miñaur S; Santos-Simarro F; Seidel V; Domínguez-Garrido E
BMC Med Genet; 2018 Mar; 19(1):36. PubMed ID: 29506490
[TBL] [Abstract][Full Text] [Related]
3. Transcriptome Analysis of iPSC-Derived Neurons from Rubinstein-Taybi Patients Reveals Deficits in Neuronal Differentiation.
Calzari L; Barcella M; Alari V; Braga D; Muñoz-Viana R; Barlassina C; Finelli P; Gervasini C; Barco A; Russo S; Larizza L
Mol Neurobiol; 2020 Sep; 57(9):3685-3701. PubMed ID: 32562237
[TBL] [Abstract][Full Text] [Related]
4. Histone Deacetylase Inhibitors Ameliorate Morphological Defects and Hypoexcitability of iPSC-Neurons from Rubinstein-Taybi Patients.
Alari V; Scalmani P; Ajmone PF; Perego S; Avignone S; Catusi I; Lonati PA; Borghi MO; Finelli P; Terragni B; Mantegazza M; Russo S; Larizza L
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34071322
[TBL] [Abstract][Full Text] [Related]
5. From Whole Gene Deletion to Point Mutations of EP300-Positive Rubinstein-Taybi Patients: New Insights into the Mutational Spectrum and Peculiar Clinical Hallmarks.
Negri G; Magini P; Milani D; Colapietro P; Rusconi D; Scarano E; Bonati MT; Priolo M; Crippa M; Mazzanti L; Wischmeijer A; Tamburrino F; Pippucci T; Finelli P; Larizza L; Gervasini C
Hum Mutat; 2016 Feb; 37(2):175-83. PubMed ID: 26486927
[TBL] [Abstract][Full Text] [Related]
6. Phenotype and genotype in 52 patients with Rubinstein-Taybi syndrome caused by EP300 mutations.
Fergelot P; Van Belzen M; Van Gils J; Afenjar A; Armour CM; Arveiler B; Beets L; Burglen L; Busa T; Collet M; Deforges J; de Vries BB; Dominguez Garrido E; Dorison N; Dupont J; Francannet C; Garciá-Minaúr S; Gabau Vila E; Gebre-Medhin S; Gener Querol B; Geneviève D; Gérard M; Gervasini CG; Goldenberg A; Josifova D; Lachlan K; Maas S; Maranda B; Moilanen JS; Nordgren A; Parent P; Rankin J; Reardon W; Rio M; Roume J; Shaw A; Smigiel R; Sojo A; Solomon B; Stembalska A; Stumpel C; Suarez F; Terhal P; Thomas S; Touraine R; Verloes A; Vincent-Delorme C; Wincent J; Peters DJ; Bartsch O; Larizza L; Lacombe D; Hennekam RC
Am J Med Genet A; 2016 Dec; 170(12):3069-3082. PubMed ID: 27648933
[TBL] [Abstract][Full Text] [Related]
7. Rubinstein-Taybi Syndrome and Epigenetic Alterations.
Korzus E
Adv Exp Med Biol; 2017; 978():39-62. PubMed ID: 28523540
[TBL] [Abstract][Full Text] [Related]
8. Clinical and molecular characterization of Rubinstein-Taybi syndrome patients carrying distinct novel mutations of the EP300 gene.
Negri G; Milani D; Colapietro P; Forzano F; Della Monica M; Rusconi D; Consonni L; Caffi LG; Finelli P; Scarano G; Magnani C; Selicorni A; Spena S; Larizza L; Gervasini C
Clin Genet; 2015 Feb; 87(2):148-54. PubMed ID: 24476420
[TBL] [Abstract][Full Text] [Related]
9. Generation of the Rubinstein-Taybi syndrome type 2 patient-derived induced pluripotent stem cell line (IAIi001-A) carrying the EP300 exon 23 stop mutation c.3829A > T, p.(Lys1277*).
Alari V; Russo S; Rovina D; Gowran A; Garzo M; Crippa M; Mazzanti L; Scalera C; Prosperi E; Giardino D; Gervasini C; Finelli P; Pompilio G; Larizza L
Stem Cell Res; 2018 Jul; 30():175-179. PubMed ID: 29944992
[TBL] [Abstract][Full Text] [Related]
10. Rubinstein-Taybi syndrome.
Kosaki R
Nihon Rinsho; 2017 Mar; 75(3):498-503. PubMed ID: 30566799
[TBL] [Abstract][Full Text] [Related]
11. Histone acetylation deficits in lymphoblastoid cell lines from patients with Rubinstein-Taybi syndrome.
Lopez-Atalaya JP; Gervasini C; Mottadelli F; Spena S; Piccione M; Scarano G; Selicorni A; Barco A; Larizza L
J Med Genet; 2012 Jan; 49(1):66-74. PubMed ID: 21984751
[TBL] [Abstract][Full Text] [Related]
12. New insights into genetic variant spectrum and genotype-phenotype correlations of Rubinstein-Taybi syndrome in 39 CREBBP-positive patients.
Pérez-Grijalba V; García-Oguiza A; López M; Armstrong J; García-Miñaur S; Mesa-Latorre JM; O'Callaghan M; Pineda Marfa M; Ramos-Arroyo MA; Santos-Simarro F; Seidel V; Domínguez-Garrido E
Mol Genet Genomic Med; 2019 Nov; 7(11):e972. PubMed ID: 31566936
[TBL] [Abstract][Full Text] [Related]
13. Mutations in CREBBP and EP300 genes affect DNA repair of oxidative damage in Rubinstein-Taybi syndrome cells.
Dutto I; Scalera C; Tillhon M; Ticli G; Passaniti G; Cazzalini O; Savio M; Stivala LA; Gervasini C; Larizza L; Prosperi E
Carcinogenesis; 2020 May; 41(3):257-266. PubMed ID: 31504229
[TBL] [Abstract][Full Text] [Related]
14. Rubinstein-Taybi syndrome in Chinese population with four novel mutations.
Yu PT; Luk HM; Lo IFM
Am J Med Genet A; 2021 Jan; 185(1):267-273. PubMed ID: 33063428
[TBL] [Abstract][Full Text] [Related]
15. Genetic heterogeneity in Rubinstein-Taybi syndrome: delineation of the phenotype of the first patients carrying mutations in EP300.
Bartholdi D; Roelfsema JH; Papadia F; Breuning MH; Niedrist D; Hennekam RC; Schinzel A; Peters DJ
J Med Genet; 2007 May; 44(5):327-33. PubMed ID: 17220215
[TBL] [Abstract][Full Text] [Related]
16. Rubinstein-Taybi syndrome in a Saudi boy with distinct features and variants in both the CREBBP and EP300 genes: a case report.
Al-Qattan MM; Jarman A; Rafique A; Al-Hassnan ZN; Al-Qattan HM
BMC Med Genet; 2019 Jan; 20(1):12. PubMed ID: 30635043
[TBL] [Abstract][Full Text] [Related]
17. Rubinstein-Taybi syndrome type 2: report of nine new cases that extend the phenotypic and genotypic spectrum.
Hamilton MJ; Newbury-Ecob R; Holder-Espinasse M; Yau S; Lillis S; Hurst JA; Clement E; Reardon W; Joss S; Hobson E; Blyth M; Al-Shehhi M; Lynch SA; Suri M;
Clin Dysmorphol; 2016 Oct; 25(4):135-45. PubMed ID: 27465822
[TBL] [Abstract][Full Text] [Related]
18. Genetic and clinical heterogeneity in Korean patients with Rubinstein-Taybi syndrome.
Choi N; Kim HY; Lim BC; Chae JH; Kim SY; Ko JM
Mol Genet Genomic Med; 2021 Oct; 9(10):e1791. PubMed ID: 34427995
[TBL] [Abstract][Full Text] [Related]
19. Syndromic features and mild cognitive impairment in mice with genetic reduction on p300 activity: Differential contribution of p300 and CBP to Rubinstein-Taybi syndrome etiology.
Viosca J; Lopez-Atalaya JP; Olivares R; Eckner R; Barco A
Neurobiol Dis; 2010 Jan; 37(1):186-94. PubMed ID: 19822209
[TBL] [Abstract][Full Text] [Related]
20. Case report: a Chinese girl like atypical Rubinstein-Taybi syndrome caused by a novel heterozygous mutation of the EP300 gene.
Bai Z; Li G; Kong X
BMC Med Genomics; 2023 Feb; 16(1):24. PubMed ID: 36797748
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
